Private equity firm taps ex-Editas CEO Jim Mullen to help expand pharma portfolio — with a nod to cell, gene therapies
Jim Mullen is lending his years of biotech CEO experience — from Biogen, Patheon and Editas — to the private equity firm Advent International.
Advent managing partner John Maldonado said Mullen will help his team expand their reach to pharmaceutical and pharma services companies “across contract manufacturing, commercialization, and research.”
“Jim’s work at Editas and Thermo Fisher have put him at the forefront of the cell and gene therapy revolution,” Carmine Petrone, managing director at Advent, added in a statement. “We are excited to partner with Jim as we continue to look for transformative companies that are enabling the development, manufacture and commercialization of these advanced therapies.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.